Financial Results, FDA Approvals, Study Results and Legal Settlements - Research Report on Aetna, Intuitive Surgical, Abbott,

   Financial Results, FDA Approvals, Study Results and Legal Settlements -
 Research Report on Aetna, Intuitive Surgical, Abbott, Questcor, and Valeant
                               Pharmaceuticals

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, November 1, 2013

NEW YORK, November 1, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Aetna Inc.
(NYSE: AET), Intuitive Surgical, Inc. (NASDAQ: ISRG), Abbott Laboratories
(NYSE: ABT), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR), and Valeant
Pharmaceuticals International, Inc. (NYSE: VRX). Today's readers may access
these reports free of charge - including full price targets, industry analysis
and analyst ratings - via the links below.

Aetna Inc. Research Report

On October 29, 2013, Aetna Inc. (Aetna) reported its Q3 2013 financial
results. The Company's total revenue increased 46.2% YoY to $13.0 billion
during the quarter. Net income attributable to Aetna was $518.6 million or
$1.38 per diluted share in Q3 2013, compared to $499.2 million or 1.47 per
diluted share in Q3 2012. Mark T. Bertolini, Aetna Chairman, CEO, and
President, said, "Aetna's diversified business model produced another solid
performance in the third quarter, which includes our first full quarter of
results from the Coventry operations. Bolstered by the acquisition and
continued strong performance in our Commercial and Medicaid businesses, Aetna
generated higher operating earnings and operating revenues year over year."
The Full Research Report on Aetna Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.analystscorner.com/r/full_research_report/cbe9_AET]

--

Intuitive Surgical, Inc. Research Report 

On October 24, 2013, Intuitive Surgical, Inc. (Intuitive Surgical) reported
results from two independent analyses that compared robotic-assisted surgery
and open surgery performed on patients with urologic cancers, which revealed
that robotic-assisted surgery results in fewer overall complications during
and after surgery, less blood loss and shorter length of hospital stay. As per
the release, in the first analysis, published in the October 2013 issue of
Cancer Treatment Reviews, the authors (Li K, Tianxin L, Xinxiang F, et al.)
reviewed the available literature on the efficacy and advantages of
robotic-assisted radical cystectomy (RARC) versus open radical cystectomy
(ORC) performed for bladder cancer. Meanwhile, in the second analysis,
published in the World Journal of Urology by Dr. Gianni Vittori from the
Universita` di Firenze, compared kidney patients who had received
robotic-assisted partial kidney removal with those who had received open
partial kidney removal. "As individuals and agencies seek to understand the
impact of robotic-assisted surgery on healthcare outcomes, evidence-based
medicine and all peer-reviewed clinical publications become increasingly
important in understanding appropriate treatment options," said Myriam Curet,
MD, Chief Medical Advisor of Intuitive Surgical. The Full Research Report on
Intuitive Surgical, Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/5f98_ISRG]

--

Abbott Laboratories Research Report

On October 25, 2013, Abbott Laboratories (Abbott) announced that the Company's
first-in-class catheter based MitraClip therapy has received U.S. Food and
Drug Administration's (FDA) approval and hence will be launched immediately in
the U.S., to provide physicians with a breakthrough treatment option for
patients suffering from mitral regurgitation. Chuck Foltz, Senior Vice
President, Vascular, Abbott, said, "FDA approval of MitraClip marks an
important milestone for Abbott as we continue to bring forward innovative
therapies to help patients live better lives. We look forward to making this
technology available to specialized centers in the U.S. with
multi-disciplinary teams experienced in the management of patients with heart
valve disease, a model that facilitates dialogue across physician specialties
and provides patients with the best treatment outcomes." The Company added
that Abbott's MitraClip repairs the mitral valve without the need for an
invasive surgical procedure. The device is delivered to the heart through the
femoral vein, a blood vessel in the leg, and once implanted, allows the heart
to pump blood more efficiently, thereby relieving symptoms and improving
patient quality of life. The Full Research Report on Abbott Laboratories -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/05c1_ABT]

--

Questcor Pharmaceuticals Inc. Research Report

On October 29, 2013, Questcor Pharmaceuticals Inc. (Questcor) reported its Q3
2013 financial results. The Company's total net sales increased 68.4% YoY to
$236.3 million during the quarter. Net income increased 69.6% YoY to $94.4
million, and net income per diluted share increased 67.0% to $1.52 in Q3 2013.
Commenting on the results, Don M. Bailey, President and CEO of Questcor, said,
"Our net sales continued to expand with rheumatology, neurology, and
nephrology exhibiting growth year-over-year. This quarter's performance was
primarily driven by a continued increase in Acthar usage among both
rheumatologists and nephrologists. Additionally, there was a record number of
paid prescriptions for MS relapse during the quarter." The Full Research
Report on Questcor Pharmaceuticals Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.analystscorner.com/r/full_research_report/a415_QCOR]

--

Valeant Pharmaceuticals International, Inc. Research Report 

On October 28, 2013, Valeant Pharmaceuticals International, Inc. (Valeant
Pharmaceuticals) announced that the Company has entered into a settlement
agreement with Anacor Pharmaceuticals (Anacor) to resolve all outstanding
disputes, including previously disclosed disputes involving Anacor and
Valeant's subsidiaries, Dow Pharmaceutical Sciences Inc. (Dow) and Medicis
Pharmaceutical Corporation (Medicis). Valeant said that it would pay Anacor
$142.5 million no later than November 8, 2013, to settle all existing and
future claims related to Anacor's intellectual property, confidential
information, and contractual rights, and the payment includes the previously
announced interim final award of damages and legal fees related to Anacor's
contractual dispute with Dow. The Full Research Report on Valeant
Pharmaceuticals International, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.analystscorner.com/r/full_research_report/9fdd_VRX]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas; +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.